Indikation von CRS und HIPEC bei peritonealen Metastasen von Pankreaskarzinomen

[1]  K. Paik,et al.  Initial Metastatic Site as a Prognostic Factor in Patients With Stage IV Pancreatic Ductal Adenocarcinoma , 2015, Medicine.

[2]  J. Cameron,et al.  Two thousand consecutive pancreaticoduodenectomies. , 2015, Journal of the American College of Surgeons.

[3]  A. Garofalo,et al.  GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study , 2014, BMC Cancer.

[4]  P. Möller,et al.  S3-Leitlinie zum exokrinen Pankreaskarzinom , 2013, Zeitschrift für Gastroenterologie.

[5]  S. Kakolyris,et al.  Preliminary Results of Hyperthermic Intraperitoneal Intraoperative Chemotherapy as an Adjuvant in Resectable Pancreatic Cancer , 2012, Gastroenterology research and practice.

[6]  P. Sugarbaker,et al.  Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer: Rationale and Report of Early Data , 2011, International journal of surgical oncology.

[7]  W. Steurer,et al.  2505 POSTER Towards More Efficacy in HIPEC – Optimization of Fluid Mechanics , 2011 .

[8]  P. Post,et al.  Systematic review and meta‐analysis of the volume–outcome relationship in pancreatic surgery , 2011, The British journal of surgery.

[9]  D. Elias,et al.  Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  H. Schlitt,et al.  Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer , 2009, Journal of surgical oncology.

[11]  F. Gansauge,et al.  Pancreatic cancer--low survival rates. , 2008, Deutsches Arzteblatt international.

[12]  S. Libutti,et al.  Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas , 2008, Cancer Chemotherapy and Pharmacology.

[13]  P. Sugarbaker,et al.  Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. , 2006, Journal of the American College of Surgeons.

[14]  S. Gallinger,et al.  Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. , 2004, Journal of the American College of Surgeons.

[15]  H. Riediger,et al.  Risk factors for complications after pancreatic head resection. , 2004, American journal of surgery.

[16]  H. van Tinteren,et al.  Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Pichlmayr,et al.  Surgery for exocrine pancreatic cancer--who are the 5- and 10-year survivors? , 1995, Oncology.

[18]  M. Büchler,et al.  [Free intraperitoneal tumors cells in pancreatic cancer--significance for clinical course and therapy]. , 1992, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.